Please sign in so that we can notify you about a reply
Indications/Uses
Salbutamol (Salbo) inhaler is indicated in adults, adolescents and children aged 4 to 11 years.
Salbutamol (Salbo) inhaler provides short-acting (4-6 hours) bronchodilation with fast onset (within 5 minutes) in reversible airways obstruction.
It is particularly suitable for the relief and prevention of asthma symptoms. It should be used to relieve symptoms when they occur and to prevent them in those circumstances recognized by the patient to precipitate an asthma attack (e.g., before exercise or unavoidable allergen exposure).
Salbutamol (Salbo) inhaler is particularly valuable as relief medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.
Salbutamol (Salbo) inhaler provides short-acting (4-6 hours) bronchodilation with fast onset (within 5 minutes) in reversible airways obstruction.
It is particularly suitable for the relief and prevention of asthma symptoms. It should be used to relieve symptoms when they occur and to prevent them in those circumstances recognized by the patient to precipitate an asthma attack (e.g., before exercise or unavoidable allergen exposure).
Salbutamol (Salbo) inhaler is particularly valuable as relief medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.
Dosage/Direction for Use
Salbutamol (Salbo) inhaler 100mcg is for oral inhalation use only.
The dose is expressed in terms of inhalations, each inhalation delivers 100mcg of salbutamol.
The dose is expressed in terms of inhalations, each inhalation delivers 100mcg of salbutamol.
Overdosage
The most common signs and symptoms of overdose with salbutamol are transient β2-agonist pharmacologically mediated events, including tachycardia, tremor, hyperactivity and metabolic effects including hypokalemia. Serum potassium levels should be monitored.
Consideration should be given to discontinuation of treatment and appropriate symptomatic therapy such as cardio-selective β-blocking agents in patients presenting with cardiac symptoms (e.g., tachycardia, palpitations).
β-blocking drugs should be used with caution in patients with a history of bronchospasm.
Consideration should be given to discontinuation of treatment and appropriate symptomatic therapy such as cardio-selective β-blocking agents in patients presenting with cardiac symptoms (e.g., tachycardia, palpitations).
β-blocking drugs should be used with caution in patients with a history of bronchospasm.
Contraindications
Salbutamol is contraindicated in patients with hypersensitivity to any component of this product.
Salbutamol must not be used to arrest uncomplicated premature labor or threatened abortion.
Salbutamol must not be used to arrest uncomplicated premature labor or threatened abortion.
Special Precautions
Patient's inhaler technique should be checked to make sure that inhaler actuation is synchronized with inspiration of breath for optimum delivery of drug to the lungs.
In the event of a previously effective dose of inhaled salbutamol failing to give relief for at least three hours, the patient should be advised to seek medical advice in order that any necessary additional steps may be taken.
Salbutamol should be administered cautiously to patients with hyperthyroidism, convulsive disorders, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation, hypertension and diabetes mellitus.
Potentially serious hypokalemia may result from β2 agonist therapy mainly from parenteral and nebulized administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids, diuretics and by hypoxia. It is recommended that serum potassium levels are monitored in such situations.
Patients requiring long-term management with bronchodilators should be kept under regular surveillance.
Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. Patients with underlying severe heart disease (e.g., ischemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnea and chest pain as they may be of either respiratory or cardiac origin.
Increasing use of short-acting inhaled β2-agonists to control symptoms indicates deterioration of asthma control. Consideration should be given to starting or increasing corticosteroid therapy.
Inhaled salbutamol can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, salbutamol should be discontinued immediately and alternative therapy instituted.
If immediate hypersensitivity reactions occur, discontinue salbutamol.
Salbutamol should be administered cautiously to patients with thyrotoxicosis.
In the event of a previously effective dose of inhaled salbutamol failing to give relief for at least three hours, the patient should be advised to seek medical advice in order that any necessary additional steps may be taken.
Salbutamol should be administered cautiously to patients with hyperthyroidism, convulsive disorders, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation, hypertension and diabetes mellitus.
Potentially serious hypokalemia may result from β2 agonist therapy mainly from parenteral and nebulized administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids, diuretics and by hypoxia. It is recommended that serum potassium levels are monitored in such situations.
Patients requiring long-term management with bronchodilators should be kept under regular surveillance.
Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. Patients with underlying severe heart disease (e.g., ischemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnea and chest pain as they may be of either respiratory or cardiac origin.
Increasing use of short-acting inhaled β2-agonists to control symptoms indicates deterioration of asthma control. Consideration should be given to starting or increasing corticosteroid therapy.
Inhaled salbutamol can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, salbutamol should be discontinued immediately and alternative therapy instituted.
If immediate hypersensitivity reactions occur, discontinue salbutamol.
Salbutamol should be administered cautiously to patients with thyrotoxicosis.
Use In Pregnancy & Lactation
Pregnancy: The use of salbutamol during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus.
Nursing Mothers: Salbutamol is probably secreted in breast milk, its use in nursing mothers is not recommended unless the expected benefits outweigh any potential risk.
Nursing Mothers: Salbutamol is probably secreted in breast milk, its use in nursing mothers is not recommended unless the expected benefits outweigh any potential risk.
Adverse Reactions
Immune system disorders: Very rare: Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse.
Metabolism and nutrition disorders: Rare: Hypokalemia.
Potentially serious hypokalemia may result from beta2 agonist therapy.
Nervous system disorders: Common: Tremor, headache.
Very rare: Hyperactivity.
Cardiac disorders: Common: Tachycardia.
Uncommon: Palpitations.
Very rare: cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles).
Unknown: Myocardial ischemia.
Vascular disorders: Rare: Peripheral vasodilatation.
Respiratory, thoracic and mediastinal disorders: Very rare: Paradoxical bronchospasm.
Gastrointestinal disorders: Uncommon: Mouth and throat irritation.
Musculoskeletal and connective tissue disorders: Uncommon: Muscle cramps.
Metabolism and nutrition disorders: Rare: Hypokalemia.
Potentially serious hypokalemia may result from beta2 agonist therapy.
Nervous system disorders: Common: Tremor, headache.
Very rare: Hyperactivity.
Cardiac disorders: Common: Tachycardia.
Uncommon: Palpitations.
Very rare: cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles).
Unknown: Myocardial ischemia.
Vascular disorders: Rare: Peripheral vasodilatation.
Respiratory, thoracic and mediastinal disorders: Very rare: Paradoxical bronchospasm.
Gastrointestinal disorders: Uncommon: Mouth and throat irritation.
Musculoskeletal and connective tissue disorders: Uncommon: Muscle cramps.
Drug Interactions
Salbutamol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants or within 2 weeks of discontinuation of such agents, because the action of salbutamol on the cardiovascular system may be potentiated.
β-adrenergic-receptor blocking agents not only block the pulmonary effect of β2-agonists, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with β-blockers.
Use of salbutamol and other β2-agonists with corticosteroids, diuretics or xanthines increases the risk of hypokalemia and monitoring of potassium concentrations is recommended in severe asthma where such combination therapy is common.
β-adrenergic-receptor blocking agents not only block the pulmonary effect of β2-agonists, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with β-blockers.
Use of salbutamol and other β2-agonists with corticosteroids, diuretics or xanthines increases the risk of hypokalemia and monitoring of potassium concentrations is recommended in severe asthma where such combination therapy is common.
Caution For Usage
Instructions for Use: Patients should be instructed in the proper use of their inhaler. During inhalation, the patient should preferably sit or stand.
Testing the inhaler: Before using for the first time or if the inhaler has not been used for a week or more remove the mouthpiece cover by gently squeezing the sides of the cover, shake the inhaler well, and release one puff into the air to make sure that it works.
Cleaning: The inhaler should be cleaned at least once a week.
Remove the metal canister from the plastic casing of the inhaler and remove the mouthpiece cover.
Rinse the plastic casing thoroughly under warm water.
Dry the plastic casing thoroughly inside and out.
Replace the metal canister into the plastic casing and put on mouthpiece cover.
Do not put the metal canister in water.
Testing the inhaler: Before using for the first time or if the inhaler has not been used for a week or more remove the mouthpiece cover by gently squeezing the sides of the cover, shake the inhaler well, and release one puff into the air to make sure that it works.
Cleaning: The inhaler should be cleaned at least once a week.
Remove the metal canister from the plastic casing of the inhaler and remove the mouthpiece cover.
Rinse the plastic casing thoroughly under warm water.
Dry the plastic casing thoroughly inside and out.
Replace the metal canister into the plastic casing and put on mouthpiece cover.
Do not put the metal canister in water.
Storage
Store at temperatures not exceeding 30°C.
Protect from heat, frost and direct sunlight.
Pressurized can. Do not puncture, break or burn even when apparently empty.
As with most inhaled medications in aerosol canisters, the therapeutic effect of this medication may decrease when the canister is cold.
The expiration date refers to the product correctly stored at the required conditions.
Protect from heat, frost and direct sunlight.
Pressurized can. Do not puncture, break or burn even when apparently empty.
As with most inhaled medications in aerosol canisters, the therapeutic effect of this medication may decrease when the canister is cold.
The expiration date refers to the product correctly stored at the required conditions.
Action
Pharmacology: Pharmacodynamics: Salbutamol is a selective β2-adrenoceptor agonist. At therapeutic doses it acts on the β2-adrenoceptors of bronchial muscle providing short acting (4-6 hours) bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction.
Pharmacokinetics: Absorption and Distribution: After administration by the inhaled route between 10% and 20% of the dose reaches the lower airways. The remainder is retained in the delivery system or is deposited in the oropharynx from where it is swallowed. The fraction deposited in the airways is absorbed into the pulmonary tissues and circulation, but is not metabolized by the lung.
Salbutamol is bound to plasma proteins to the extent of 10%.
Metabolism and Excretion: The swallowed portion of an inhaled dose is absorbed from the gastrointestinal tract and undergoes considerable first-pass metabolism to the phenolic sulfate. The portion deposited in the lung is not metabolized by the lung. On reaching the systemic circulation it becomes accessible to hepatic metabolism and is excreted primarily in the urine as unchanged drug and as the phenolic sulfate.
Most of the dose of salbutamol given intravenously, orally or by inhalation is excreted within 72 hours.
Pharmacokinetics: Absorption and Distribution: After administration by the inhaled route between 10% and 20% of the dose reaches the lower airways. The remainder is retained in the delivery system or is deposited in the oropharynx from where it is swallowed. The fraction deposited in the airways is absorbed into the pulmonary tissues and circulation, but is not metabolized by the lung.
Salbutamol is bound to plasma proteins to the extent of 10%.
Metabolism and Excretion: The swallowed portion of an inhaled dose is absorbed from the gastrointestinal tract and undergoes considerable first-pass metabolism to the phenolic sulfate. The portion deposited in the lung is not metabolized by the lung. On reaching the systemic circulation it becomes accessible to hepatic metabolism and is excreted primarily in the urine as unchanged drug and as the phenolic sulfate.
Most of the dose of salbutamol given intravenously, orally or by inhalation is excreted within 72 hours.
MedsGo Class
Antiasthmatic & COPD Preparations
Features
Dosage
100mcg
Ingredients
- Salbutamol
Packaging
Metered Dose Inhaler 200act.
Generic Name
Salbutamol
Registration Number
DR-XY47359
Classification
Prescription Drug (RX)
Product Questions
Questions
